COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF FURAZIDINE DRUGS IN PATIENTS WITH ACUTE CYSTITIS IN OUT-PATIENT PRACTICE
The aim of the study was comparative clinical and economical analysis of the use of the treatment regimen for acute uncomplicated cystitis with furazidine drugs (Urofuragin® tablets 50 mg, 30 pcs., Adamed Consumer Healthcare SA, Poland; Furamag® capsules 50 mg, 30 pcs., Olainfarm, Latvia; Furagin® tablets 50 mg, 30 pcs., Olainfarm, Latvia) in outpatient practice. The study was retrospective comparative with the inclusion of data from medical records of outpatients with primary acute uncomplicated cystitis. For pharmacoeconomic examination methods of analyzing of cost-effectiveness, “budgetary impact”, calculating missed opportunities taking into account direct costs and the effectiveness of therapy based on the assessing of the dynamics of symptoms of cystitis with the ACSS scale, urinalysis by microscopy, bacteriological examination of the urine were used. An ultrasound scans of kidneys and bladder were analyzed to exclude of secondary cystitis. Medical records of patients (women, n=90, age 18-55 years) with acute uncomplicated cystitis were systematized according to inclusion/exclusion criteria. All patients were divided into 3 groups: group 1 (n=30) received therapy with Urofuragin® 100 mg (2 tablets) 3 times a day after meals, 7 days; group 2 (n=30) received therapy with Furamag® 100 mg (2 capsules) 3 times a day after meals, 7 days; group 3 (n=30) received Furagin® 100 mg (2 tablets) 3 times a day after meals, 7 days. In groups 1, 2 and 3 on the 23rd day of analysis, repeated courses of therapy with Urofuragin® (n=7), Furamag® (n=10) and Furagin® (n=13) 100 mg 2 times a day for 7 days were used. The main etiological factor of cystitis in 83.3% of patients was E. coli . Nausea was observed in 2 patients in group 2 and 3, respectively; in group 3 the diarrhea was detected in 1 patient. The treatment of acute uncomplicated cystitis with the use of Urofuragin® is the most economically feasible in terms of cost-effectiveness ratio, efficacy and safety compared with the strategy of Furamag® and Furagin® for 7 days while maintaining the treatment results for 2 weeks from the start of therapy , and also saves significant budget funds (up to 916733 rubles). Saved funds allow the use of effective therapy technology in addition to significant number of patients (up to 168 patients).